Typhoid fever is a bacterial infection caused by the bacterium Salmonella typhi. The symptoms of a typhoid infection include persistent high fever, headache, diarrhea, weakness, and loss of appetite. This infection can spread throughout the body and affect many organs. In addition, without prompt treatment, typhoid fever can also cause serious complications which can lead to the patient's death. Hence, a typhoid vaccine has become crucial as it helps prevent typhoid fever in humans. There are two common types of typhoid vaccines which include inactivated (killed) typhoid vaccine and attenuated (weakened) typhoid vaccine.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in December, 2019. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since its outbreak,, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.
However, with COVID-19, the supply chain of the raw materials required to manufacture vaccines for typhoid fever has been disrupted in many countries. In addition, the market growth of pharmaceuticals is on decline as the manufacturers of drugs and vaccines have slowed down their production because of the pandemic. This, in turn, is expected to have a significant impact on the typhoid fever vaccine market.
Top Impacting Factors
There has been increased research on typhoid vaccines in emerging markets such as Europe and Asia-Pacific. This factor is acting as a driver for the typhoid fever vaccine market.
In addition, the governments of many developed nations are investing in manufacturing typhoid vaccines. This is also leading to the development of better and highly advanced typhoid fever vaccines.
The number of typhoid cases is highly prevalent in many developing nations. With this, there is also a high mortality rate associated with typhoid which has increased the demand for typhoid vaccines. Hence, this demand is also helping in the growth of the typhoid fever vaccine market.
However, the less availability of these vaccines in remote areas and strict regulations associated with the launch of new vaccines are some of the factors that hinder the growth of the typhoid fever vaccine market.
Key Market Trends
In 2019, the highest share of the typhoid fever vaccine market was accounted for by the capsular polysaccharide segment. The growth of this particular typhoid fever vaccine segment is attributed to its effectiveness in preventing typhoid infections.
North America holds the major share of the market owing to the increase in awareness among citizens which has led to the demand for typhoid vaccines for infants, children as well as adults. The easy availability of vaccines in the U.S. has also fueled the market growth in this region.
Furthermore, the typhoid fever vaccine market in the Asia-Pacific is expected to grow at a significant rate due to government initiatives being taken for immunization against typhoid fever and a large population base, especially in India and China.
In Latin America, Brazil is likely to be one of the prominent players in the typhoid fever vaccine market due to developing healthcare infrastructure and investments by major key players in the country who have established vaccine manufacturing units in the nation.
Key Benefits of the Report
- This study presents the analytical depiction of the typhoid fever vaccine industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the typhoid fever vaccinemarket share.
- The current market is quantitatively analyzed to highlight the growth scenario of the typhoid fever vaccine market.
- Porter’s five forces analysis illustrates the potency of buyers and suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Typhoid Fever Vaccine Report
- Which are the leading players active in the typhoid fever vaccine market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the typhoid fever vaccine market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps in the market?
- What are the impacts of COVID-19 on the industry?
- What is a typhoid fever vaccine?
- What are the current and predicted trends of the market?
Typhoid Fever Vaccine Market Report Highlights
| Aspects | Details |
 By Vaccine Type |
|
 By Route of Administration |
|
 By End User |
|
 By Region |
|
 Key Market Players | Shanghai institute of biological products co., ltd., GlaxoSmithKline, Sanofi, Paxvax Inc., Prokarium Ltd., China National Biotec Group, PT Bio Farma, Bharat Biotech, BIO-MED, Scandinavian Biopharma |
Loading Table Of Content...
